MedTrace Logo

Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors

NCT01878396 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2016-10-03

No results posted yet for this study

Summary

The purpose of this study, is to evaluate Circulating Melanoma Cell (CMC) changes in Metastatic Melanoma (MM) patients, undergoing treatment with selective inhibitors of mutated BRAF.

Conditions

Interventions

DRUG

Anti-B-RAF

Sponsors & Collaborators

  • Janssen Diagnostics, LLC

    collaborator INDUSTRY

  • Istituto Oncologico Veneto IRCCS

    lead OTHER

Principal Investigators

  • Paola Zanovello, Phd · Padua University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2016-12-31
Completion
2017-12-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01878396 on ClinicalTrials.gov